Krill Oil Study Compared to Fish Oil

University of Manitoba24 enrolled

Overview

The main purpose of the study is to evaluate the absorption of omega-3 fatty acids into the blood following consumption of krill oil compared with fish oil and placebo.

The main purpose of the study is to evaluate the absorption of omega-3 fatty acids into the blood following consumption of krill oil compared with fish oil and placebo. An additional purpose is to evaluate the lipid-lowering efficacy and safety of consumption of Krill Oil and Fish Oil to a placebo product. It has been shown that the ingestion of Krill Oil leads to better absorption of omega-3 fatty acids compared to ingestion of Fish Oil. It was also shown that consumption of krill oil and fish oil result in a favorable modification of lipid profiles. Therefore, it is anticipated that consumption of these krill oil and fish oil will improve lipid profile, as well as other health-related markers and will be safe and well tolerated.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Healthy Volunteers

Interventions

Krill oilDIETARY_SUPPLEMENT

Krill oil:Total omega-3 fatty acids: 560-660 mg and Astaxanthin: 1800 µg

Fish OilDIETARY_SUPPLEMENT

Fish oil: Total omega-3 fatty acids: 560-660 mg

Eligibility

Sex: ALLMin age: 18 YearsMax age: 49 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * healthy men and premenopausal not pregnant or nursing women between 18 and 49 years old. Exclusion Criteria: * smokers * rheumatoid arthritis * chronic illness * cardiovascular problems * dyslipidemia * liver and kidney disease * diabetes * endocrine or metabolic disease * inflammatory bowel disease * pancreatitis * gallbladder or biliary disease * neurological/psychological disease * bleeding disorders * experienced platelet abnormalities * gastrointestinal disorders that could interfere with fat absorption * hypertension * history of cancer * an intention to lose weight * use of anticoagulant * serum triglycerides (TG) \>200 mg/dL, and/or total cholesterol (TC) \>240 mg/dL, and/or LDL-cholesterol (LDL-C) \>160 mg/dL * hypertension or lipid lowering medications * consumption of more than one alcoholic drinks/day * Consumption of more than one fish or seafood serving * one month prior to the start of the study * omega-6 fatty acids in the past 6 months * planned to consume seafood products or fish or to use any omega-3 or omega-6 fatty acids nutritional supplements at anytime in the duration of the study * planned to to become pregnant during the study period * BMI\>28 * allergies to fish seafood or corn

Locations (1)

Richardson Centre for Functional Foods and Nutraceuticals

Winnipeg, Manitoba, Canada

Outcomes

Primary Outcomes

Bioavailability

Time frame: 1 month

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.